George Medicines Announces GMRx2 NDA Filing to FDA

August 6, 2024

George Medicines' GMRx2, a triple combination single pill for hypertension, achieved primary efficacy and safety endpoints in Phase III studies, aiming to transform treatment.

Highlighted Terms

kidney failure Federation Asset Management hypertension heart attacks George Health heart failure The George Institute for Global Health George Medicines dementia stroke telmisartan Brandon Capital BUPA type 2 diabetes indapamide amlodipine

Related News

drugs.com

George Medicines Announces GMRx2 NDA Filing to FDA

George Medicines' GMRx2, a triple combination single pill for hypertension, achieved primary efficacy and safety endpoints in Phase III studies, aiming to transform treatment.